Skip to main content
Clinical Trials/ISRCTN64725429
ISRCTN64725429
Completed
Not Applicable

Comparative evaluation of immunogenicity and reactogenicity of monovalent type 2 and 3 oral poliovirus vaccines (mOPV 2 and mOPV3) versus trivalent oral poliovirus vaccine (tOPV), and bivalent oral poliovirus vaccine (bOPV) versus monovalent types 1 and 3 oral poliovirus vaccines, respectively: a randomised double-blind trial

Panacea Biotec Limited (India)0 sites900 target enrollmentNovember 26, 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Panacea Biotec Limited (India)
Enrollment
900
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 26, 2008
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Panacea Biotec Limited (India)

Eligibility Criteria

Inclusion Criteria

  • 1\. Healthy newborns (either sex) (greater than or equal to 2\.50 kg birth weight, apgar score at 5 min greater than or equal to 9\) at the study sites (large maternity hospitals)
  • 2\. Residing within a relatively short and easily accessible distance (less than 30 km)
  • 3\. Not planning to travel away during entire the study period (birth \- 2 months)

Exclusion Criteria

  • 1\. Newborns requiring hospitalisation
  • 2\. Birth weight below 2\.50 kg
  • 3\. Apgar score at 5 min less than 9
  • 4\. Residence greater than 30 km from study site
  • 5\. Families expecting to be absent during the 60\-day study period
  • 6\. A diagnosis or suspicion of immunodeficiency disorder (either in the participant or in a member of the immediate family) will render the newborn ineligible for the study

Outcomes

Primary Outcomes

Not specified

Similar Trials